<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339532</url>
  </required_header>
  <id_info>
    <org_study_id>GEP13</org_study_id>
    <nct_id>NCT02339532</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status</brief_title>
  <acronym>NeoTOP</acronym>
  <official_title>Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this multicenter study will therefore be to evaluate pathologic&#xD;
      complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® -&#xD;
      PERTUZUMAB] and a non anthracycline-based regimen [TAXOTERE® - CARBOPLATINE - HERCEPTIN® -&#xD;
      PERTUZUMAB] according to the presence or not of TOP2A gene amplification in a population of&#xD;
      breast cancer patients with HER2 overexpression.&#xD;
&#xD;
      A very important objective of the study will be the evaluation of biomarkers that predict&#xD;
      response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II study, we propose a treatment strategy that not only takes advantage of the&#xD;
      complementary action of trastuzumab and pertuzumab but also the relevance of an&#xD;
      anthracycline-based regimen. Indeed, besides the cardiac toxicity that can be induced by&#xD;
      these three agents, anthracycline chemotherapy may not confer benefit to all patients.&#xD;
&#xD;
      The underlying scientific hypothesis is based on data from the NEOSPHERE neoadjuvant trial&#xD;
      showing that addition of pertuzumab to trastuzumab plus docetaxel improved the pCR rate (46%&#xD;
      versus 29% without pertuzumab) in T2-T3 tumors. Therefore, we hypothesize that for smaller&#xD;
      tumors (T1c), the pCR rate should be higher, on the order of 60% in patients with the&#xD;
      coamplification (with anthracycline therapy) and 55% for the group without coamplification&#xD;
      (without anthracycline therapy). The sample size of 90 patients (45 per group) planned for&#xD;
      the phase II study will allow 15% precision with the expected pCR rates of 60% (95%CI:&#xD;
      45%-75%) for patients with coamplification and 55% (95%CI: 40%-70%) for those without&#xD;
      coamplification. In addition, exploratory analyses will aim to identify predictive markers of&#xD;
      pCR in order to target biologically defined subpopulations in which pCR rates might even be&#xD;
      higher.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Actual">October 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response according to Chevallier classification</measure>
    <time_frame>20 weeks</time_frame>
    <description>on surgical specimen and lymph nodes at the time of the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of response to both treatment regimens (anthracycline-based and non anthracycline-based regimens)</measure>
    <time_frame>20 weeks</time_frame>
    <description>on surgical specimen and lymph nodes at the time of the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR), according to Sataloff's classification</measure>
    <time_frame>20 weeks</time_frame>
    <description>on surgical specimen and lymph nodes at the time of the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and radiological response according to the WHO criteria</measure>
    <time_frame>after two cycles of treatment and after the end of treatment</time_frame>
    <description>on mammography and breast echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI CTC-AE v4.0 criteria</measure>
    <time_frame>during on-treatment period (defined as the period from the first dose of study medication up to 30 days of the last dose</time_frame>
    <description>according the occurrence of adverse events and toxicities assessed every week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>up to 60 months</time_frame>
    <description>The PFS is defined as the time from the first administration of treatment to progression or death of any cause, if progression has not been documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 60 months</time_frame>
    <description>The OS is defined as the time from the first administration of treatment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TOP2A amplified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w&#xD;
5-Fluorouracil (5-FU) 500 mg/m²&#xD;
Epirubicin 100 mg/m²&#xD;
Cyclophosphamide 500 mg/m²&#xD;
Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:&#xD;
Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.&#xD;
Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.&#xD;
DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOP2A not amplified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles&#xD;
Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.&#xD;
Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.&#xD;
DOCETAXEL 75 mg/m² IV q3w&#xD;
CARBOPLATIN AUC 6 IV q3w&#xD;
The Calvert formula will be used to calculate the dose of carboplatin:&#xD;
Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC100</intervention_name>
    <description>3 cycles of FEC 100 administered IV q3w&#xD;
5-Fluorouracil (5-FU) 500 mg/m²&#xD;
Epirubicin 100 mg/m²&#xD;
Cyclophosphamide 500 mg/m²</description>
    <arm_group_label>TOP2A amplified</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV</description>
    <arm_group_label>TOP2A amplified</arm_group_label>
    <arm_group_label>TOP2A not amplified</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.</description>
    <arm_group_label>TOP2A amplified</arm_group_label>
    <arm_group_label>TOP2A not amplified</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.</description>
    <arm_group_label>TOP2A amplified</arm_group_label>
    <arm_group_label>TOP2A not amplified</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>CARBOPLATIN AUC 6 IV q3w</description>
    <arm_group_label>TOP2A not amplified</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged ≥ 18;&#xD;
&#xD;
          -  Patient has histologically confirmed breast cancer, with a clinical tumour diameter of&#xD;
             &gt; 1 cm (cT1c, cT2-3 or T4a)-&#xD;
&#xD;
          -  Any N status&#xD;
&#xD;
          -  No clinically or radiologically detectable metastases (M0);&#xD;
&#xD;
          -  HR negative (both ER and PR &lt; 10% by IHC); for T1c status, otherwise HR negative or&#xD;
             positive&#xD;
&#xD;
          -  Her-2 positive (i.e. IHC score 3+ or FISH/SISH/CISH positive);&#xD;
&#xD;
          -  Performance status ≤ 1 (according to WHO criteria);&#xD;
&#xD;
          -  Patients not previously treated by surgery, radiotherapy, hormone therapy or&#xD;
             chemotherapy;&#xD;
&#xD;
          -  Hæmatology: Absolute neutrophil count (ANC) ≥1,500/mm³; Platelets ≥100,000/mm³; Total&#xD;
             white blood cell count (WBC) ≥3.000/mm³; Hb&gt; 9g/dl;&#xD;
&#xD;
          -  Hepatic Function: Total bilirubin ≤1.5 time the upper normal limit (UNL); ASAT ≤&#xD;
             1.5xUNL; ALAT ≤ 1.5xUNL; Alkaline phosphatase ≤ 2.5xUNL;&#xD;
&#xD;
          -  Renal Function: Serum creatinine ≤1.5xUNL (and if Serum creatinine &gt;1.5xUNL,&#xD;
             Creatinine clearance ≥50 mL/min (MDRD formula);&#xD;
&#xD;
          -  Metabolic Function: Magnesium ≥ lower limit of normal; Calcium ≥ lower limit of&#xD;
             normal;&#xD;
&#xD;
          -  Patient with not controlled heart disease and for whom anthracyclines are not&#xD;
             contraindicated. Cardiac ejection fraction ≥50% measured by MUGA or ECHO done within 4&#xD;
             weeks before inclusion;&#xD;
&#xD;
          -  Patient agreeing to use effective contraception during and for ≥ 7 months after&#xD;
             completion of study treatment;&#xD;
&#xD;
          -  Patient able to comply with the protocol;&#xD;
&#xD;
          -  Patient must have signed a written informed consent form prior to any study specific&#xD;
             procedures;&#xD;
&#xD;
          -  Patient must be affiliated to a Social Health Insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral or multifocal breast cancer;&#xD;
&#xD;
          -  Non-measurable tumour;&#xD;
&#xD;
          -  Any form of breast cancer other than those described in the inclusion criteria,&#xD;
             particularly inflammatory and/or overlooked forms (T4b or T4d);&#xD;
&#xD;
          -  HER2 negative status (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH&#xD;
             negative);&#xD;
&#xD;
          -  RH positive (ER or PR ≥ 10% by IHC) ;&#xD;
&#xD;
          -  Patient has a history of second cancer, with exception of in situ cervical cancer or&#xD;
             basocellular skin cancer which is regarded as cured;&#xD;
&#xD;
          -  Patient has already been treated for new breast cancer;&#xD;
&#xD;
          -  Patients have already undergone surgery for their disease or have had primary axillary&#xD;
             dissection;&#xD;
&#xD;
          -  Prior docetaxel administration or anti-HER2 antibody therapy (e.g.: trastuzumab or&#xD;
             pertuzumab);&#xD;
&#xD;
          -  Patients with other concurrent severe and/or uncontrolled medical disease which could&#xD;
             compromise participation in the study, such as, but not limited to:&#xD;
&#xD;
               -  Heart or kidney failure, medullary, respiratory or liver failure, dyspnea&#xD;
&#xD;
               -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
                  unstable angina, symptomatic congestive heart failure, serious uncontrolled&#xD;
                  cardiac arrhythmia, poorly controlled hypertension) ≤ 1 year before enrollment&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Significant neurological or psychiatric abnormalities&#xD;
&#xD;
               -  Symptomatic or progressive disorder of the central nervous system (CNS) or&#xD;
                  metastasis at the initial check-up.&#xD;
&#xD;
               -  Peripheral neuropathy &gt; grade 2&#xD;
&#xD;
               -  Acute urinary infection, ongoing hemorrhagic cystitis;&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity;&#xD;
&#xD;
          -  Sensitivity to any of the study medications or any of the ingredients or excipients of&#xD;
             these medications;&#xD;
&#xD;
          -  Patients receiving of the concomitant medications with phenytoin;&#xD;
&#xD;
          -  Patients who received any other investigational drugs within 30 days of initiation of&#xD;
             treatment and/or during the study;&#xD;
&#xD;
          -  Must not have had a major surgical procedure within 30 days of initiation of&#xD;
             treatment;&#xD;
&#xD;
          -  Pregnant women, women who are likely to become pregnant or are breast-feeding;&#xD;
&#xD;
          -  Patients with any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial;&#xD;
&#xD;
          -  Patients with history of non compliance to medical regimens or unwilling or unable to&#xD;
             comply with the protocol;&#xD;
&#xD;
          -  Individual deprived of liberty or placed under the authority of a tutor.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Ange MOURET REYNIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Site Rene Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital D'Instructions Des Armees</name>
      <address>
        <city>Saint-Mande</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-positive</keyword>
  <keyword>non-metastatic</keyword>
  <keyword>TOP2A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

